Joining Forces: Bmi1 Inhibition and Cisplatin Curb Squamous Carcinogenesis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28475877.
- Also identified by DOI 10.1016/j.stem.2017.04.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Head and neck squamous cell carcinomas (HNSCCs) are refractory to therapeutic interventions. Chen et al. (2017) show that mouse and human HNSCCs and their metastases depend on Bmi1-expressing cancer stem cells and AP1 signaling and that simultaneously inhibiting Bmi1 or AP1, combined with Cisplatin, reduces tumor growth effectively in preclinical models.
Medical subject headings
- Carcinoma, Squamous Cell
- Cisplatin
- Head and Neck Neoplasms
- Polycomb Repressive Complex 1